A growing body of evidence indicates that earlier, more frequent (treatment density) and more intensive (treatment intensity) neurorehabilitation following concussion or mild traumatic brain injury (mTBI) is associated with improved functional outcomes and greater symptom reduction. Multiple studies demonstrate that active, multimodal, and targeted rehabilitation interventions lead to faster recovery compared with prolonged rest alone, particularly in patients with persistent post-concussion symptoms.
Consistent with this evidence, the National Institutes of Health (NIH) has noted a shift away from extended rest toward early, active, and targeted neurorehabilitation as a more effective strategy for promoting recovery following concussion.
The TDR per Week vs. GyroStim Treatment Density comparison illustrates an exponential therapeutic dose–response (TDR), demonstrating that increasing GyroStim treatment density is associated with disproportionately greater clinical gains at higher treatment frequencies.
Collectively, these findings suggest a meaningful evolution in the management of persistent post-concussion syndrome. Rather than incremental improvement over months, high-density, multimodal neurorehabilitation with GyroStim has been associated with recovery timelines measured in weeks—and in some cases days—substantially faster than conventional rehabilitation approaches. Supported by FDA clearance, FDA Breakthrough Device designation, and a growing body of prospective research, GyroStim represents an emerging therapeutic paradigm with the potential to accelerate functional recovery, reduce long-term disability and overall healthcare burden, and improve quality of life for millions of individuals each year.
Clinical chart review data courtesy of Dr. Kim Fox, Clinical Director, AVORA Health, Asheville, North Carolina.
